Amfexa® (dexamfetamine sulfate)
Amfexa® can be used as part of a comprehensive treatment programme
for attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years
when response to previous methylphenidate treatment is considered clinically inadequate1.
Amfexa tablets are not licensed for use in adults for the treatment of ADHD.
Dosing & administration
- At the start of treatment with Amfexa®, dose titration is necessary1
- Recommended starting daily dose is 5 mg once or twice daily e.g. at mealtimes1
- Dose can be increased if necessary by weekly increments of 5 mg daily, depending on how well it’s tolerated and working. The maximum daily dose in children and adolescents usually is 20 mg, although doses of 40 mg may in rare cases be necessary for optimum titration1
- When treating ADHD, it helps to carefully choose the time treatment is taken so it combats any school or behavioural difficulties most effectively1
Safety and Monitoring
Access our full safety and monitoring information or please refer to section 4 of the SPC.
References
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.
Date of Preparation: August 2024 UK-AMF-2024-1646-v2
Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should be reported to MEDICE UK, Medical Information Tel: 0204 582 2845, medicalinformation@medice.co.uk
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should be reported to MEDICE UK, Medical Information Tel: 0204 582 2845, medicalinformation@medice.co.uk